Celldex Therapeutics (NASDAQ: CLDX) announced results from a Phase 2 study of barzolvolimab in patients with cold urticaria and symptomatic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE